Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India.

Authors :: Gupta N
Verma RK
Prinja S
Dhiman RK
Source :: Journal of clinical and experimental hepatology [J Clin Exp Hepatol] 2019 Jul-Aug; Vol. 9 (4), pp. 468-475. Date of Electronic Publication: 2018 Oct 31.
Publication Year :: 2019
Abstract: Background: Majority of patients of hepatocellular carcinoma (HCC) in India present in advanced stages, when curative treatment options are limited. We undertook this study to assess the cost-effectiveness of treating advanced HCC patients with sorafenib compared with best supportive care (BSC).<br />Methods: A Markov model was parameterized to model the lifetime costs and consequences of treating advanced HCC patients with sorafenib versus BSC using a societal perspective. Cost of routine care, diagnostics, management of complications in both the arms and management of adverse effects of sorafenib treatment were considered. A probabilistic sensitivity analysis was undertaken to assess the effect of parameter uncertainty.<br />Results: The incremental cost and benefit gained by treating HCC using sorafenib was Indian rupees 94,182 ($1459) and 0.19 quality adjusted life years (QALYs) per patient, implying an incremental cost of Indian rupees 507,520 ($7861) per QALY gained.<br />Conclusions: Sorafenib is not cost-effective for use in advanced hepatocellular carcinoma treatment in India.

Full Text Access

Tools